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Rat liver contains a limited number of binding sites for hepatic lipase
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The binding of hepatic lipase to rat liver was studied in an ex vivo
perfusion model. The livers were perfused with media containing
partially purified rat hepatic lipase or bovine milk lipoprotein
lipase. The activity of the enzymes was determined in the
perfusion media before and after passage through the liver.
During perfusion with a hepatic-lipase-containing medium the
lipase activity in the medium did not change, indicating that
there was no net binding of lipase by the liver. In contrast, more
than 80% of the lipoprotein .lipase was removed from the
medium. This lipoprotein lipase activity could be recovered into
the perfusion medium completely by heparin perfusion of the
liver. If livers, first depleted of hepatic lipase by heparin, were
subsequent perfused with a hepatic-lipase-containing medium,
90 + 24 m-units of the lipase activity was bound per g of liver (up
to 1000 m-units/total liver). However, heparin treatment of the
liver decreases the ability of the liver to re-bind hepatic lipase by
80 %. Perfusion of rat livers with 0.3 M NaCl released 60 % of
the lipase activity into the medium. Upon subsequent perfusion
of these livers with hepatic-lipase-containing media, 541 + 164 m-
units of hepatic lipase could be bound per g of liver (up to
5000 m-units/total liver). The binding of hepatic lipase was also
studied in livers of corticotropin (ACTH)-pre-treated rats. In
these rats also, hepatic lipase bound only to livers which had
been pre-perfused with heparin or 0.3 M NaCl. After heparin
pre-perfusion, 88 + 12 m-units of hepatic lipase could be bound
per g of liver, similar to that with livers ofcontrol rats not treated
with ACTH. After prior salt perfusion, however, the capacity of
the livers of ACTH-pre-treated rats to bind hepatic lipase was
212 + 60 m-units/g of liver. This is less than in livers of control
rats (541 + 164 m-units/g of liver). These results indicate that in
rat liver the binding ofhepatic lipase is heterogeneous in character
and consists of heparin-resistant and heparin-sensitive com-
ponents. The hepatic-lipase binding capacity of the liver is
saturable and fully utilized under various conditions. The
heparin-sensitive binding capacity is lowered in ACTH-treated
rats, whereas the heparin-resistant binding is unaffected. We
postulate that the functional hepatic lipase activity can be
regulated by changes in the binding capacity of the liver.
INTRODUCTION
Heparin releases two lipases into the bloodstream, lipoprotein
lipase and hepatic lipase [1-4]. Lipoprotein lipase originates from
extra-hepatic tissues and is involved in the metabolism of
triacylglycerol-rich lipoproteins. Hepatic lipase is present in the
liver and is believed to play a role in the metabolism of high-
density lipoproteins, intermediate-density lipoproteins and
chylo-micron remnants [5-9]. Both lipoprotein lipase and hepatic
lipase are synthesized and secreted by parenchymal cells and are
bound specifically to the endothelial-cell lining [10-15]. It is
generally assumed that both hepatic lipase and lipoprotein lipase
are bound to heparan sulphates at the endothelium [15-18].
A heparan sulphate proteoglycan and a heparin-releasable
lipoprotein-lipase-binding protein (HRP) have been identified as
the binding sites for lipoprotein lipase in bovine aortic endothelial
cells [19,20]. In vitro, a saturable binding of lipoprotein lipase is
observed with bovine aortic endothelial cells, and it has been
suggested that the binding capacity for lipoprotein lipase is
determined by the number of heparan sulphate molecules in the
extracellular matrix [15]. However, in situ no saturation of
lipoprotein lipase binding was observed in perfused rat hearts
[21], indicating that, at least in hearts, the binding sites for
lipoprotein lipase are not fully occupied under normal conditions.
Lipoprotein lipase can also be bound to the liver in a non-
saturable manner, and binding of lipoprotein lipase to the liver
is considered as part of the degradation route of lipoprotein
lipase [22-24]. Additionally, binding of lipoprotein lipase to the
liver may play a role in the uptake of lipoproteins by the liver
[25-28].
Less is known about the binding of extracellularly located
hepatic lipase in the liver. Heparan sulphates appear also to be
involved in the binding of hepatic lipase to HepG2 cells [29].
Hepatic lipase binds to isolated non-parenchymal liver cells in a
saturable manner [11]. Previously we have shown that the hepatic
lipase activity is greatly lowered in hypercorticism [12]. Part of
the lowering may be due to decreased synthesis and secretion
ofthe enzyme by the parenchymal liver cells, as studied in cortico-
tropin (ACTH)-treated animals. Besides the decreased synthesis,
also the maximal binding capacity of the non-parenchymal cells
for hepatic lipase is decreased after prior treatment ofthe animals
with ACTH [12]. This suggests that the binding capacity of liver
endothelium for hepatic lipase may be limited. Almost all hepatic
lipase is extracellularly located, implying that the number of
hepatic-lipase binding sites determines the functionally expressed
activity of the lipase in the liver. However, a decrease in maximal
binding capacity hardly affects the expressed activity if only a few
binding sites are occupied under most conditions. Therefore, we
studied the availability of hepatic-lipase binding sites in livers of
control and ACTH-pre-treated rats in situ.
MATERIALS AND METHODS
Animals
Normally fed male Wistar rats (250-300 g) were used. They were
housed under controlled conditions: temperature 20-22 °C, light
on 07:00-19:00 h. Hypercorticism was induced by treatment
with a synthetic ACTH analogue (Synacthen-depot, 2 mg/ml)
[12,30]. Synacthen was administered during 3 days sub-
Abbreviations used: ACTH, corticotropin; KRB, Krebs-Ringer bicarbonate buffer.
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cutaneously (0.2 mg/kg body weight). Synacthen-treated rats are
indicated as 'ACTH-rats'.
Isolation of lipoprotein lipase and hepatic llpase
Lipoprotein lipase was purified from bovine milk as described by
Tajima and co-workers [31]. Lipoprotein lipase was first bound
to Sepharose-heparin and eluted with 1.5 M NaCl/10 mM
sodium phosphate, pH 6.8. Fractions containing lipoprotein
lipase activity were pooled and diluted to 0.5 M NaCl. After
binding to Sepharose-heparin again, lipoprotein lipase activity
was eluted with a linear salt gradient of 1-2 M NaCI/lO mM
sodium phosphate, pH 6.8. The eluted lipoprotein lipase activity
was loaded on to a hydroxyapatite column equilibrated with
10 mM sodium phosphate, pH 6.8. After elution with 0.3 M
sodium phosphate/0.5 M NaCl/20% glycerol, pH 6.8, the
enzyme was precipitated by dialysis against 3.6 M (NH4)2SO4.
The precipitate was collected by centrifugation, and the purified
lipoprotein lipase was suspended in 20 mM sodium phosphate/
50% glycerol, pH 6.8 (specific activity 44150 m-units/mg of
protein).
Hepatic lipase was isolated from heparin-containing rat liver
perfusates [12]. Rat livers were perfused through the portal vein
at 37 °C with a Krebs-Ringer bicarbonate buffer (KRB: 140 mM
NaCl, 5.4 mM KCI, 0.8 mM Na2HP04, 2.5 mM CaCl2, 8.1 mM
MgSO4, 25 mM NaHCO3, 6.0 mM glucose, pH 7.4) containing
1 % BSA at a flow rate of 3-4 ml/min per g of liver. After 10 min
pre-perfusion, the perfusion was continued for 5 min with the
same medium to which 10% glycerol and 5 units/ml heparin
were added. The perfusates were collected on ice and applied to
a Sepharose-heparin column (1.5 cm x 9 cm; flow rate 35 ml/h,
4 °C). The column was washed with 3 column volumes of 0.2 M
NaCl/10 mM sodium phosphate/ IO% glycerol, pH 7.4. Lipase
activity was eluted with the same buffer containing 1 M NaCl
and 1 % BSA; 1 ml fractions were collected. The five peak
fractions were combined and the buffer was changed to KRB
containing 1 % BSA by gel-filtration using PDIO columns.
Liver perfusion
Livers were perfused in situ as described by Seglen [32]. The
animals were anaesthetized with diethyl ether. The portal vein
was cannulated and the perfusion was started immediately with
KRB at a flow rate of 3-4 ml/min per g of liver. The vena cava
superior was cannulated just above the diaphragm and the vena
cava inferior was ligated just above the right renal vein. After a
10 min wash-out period, the perfusion medium was changed to
KRB containing 1% BSA and perfusion was continued at
0-4 °C; 5 min later hepatic lipase or lipoprotein lipase was added
to the medium. The perfusion was continued in a recirculating
manner during 10 min with a total volume of 50 ml. At the
indicated time points, samples from the medium were taken for
the determination of hepatic lipase or lipoprotein lipase. After
the reperfusion period the liver was flushed for 5 min with KRB
containing 1 % BSA to remove unbound enzyme. Finally, heparin
(5 units/ml) was added to the buffer, and the heparin perfusate
was collected on ice. In some experiments livers, after the 10 min
wash-out period, were perfused with 0.3 M NaCl by adding
0.16 M NaCl to the perfusion medium. The perfusion with 0.3 M
NaCl during 10 min was always followed by perfusion for 5 min
with 0.22 M NaCl and 5 min with KRB, successively. Binding of
hepatic lipase to these 0.3 M NaCl-pre-perfused livers was
performed as described above. It was found that the salt
perfusion, provided that the salt concentration was gradually
lowered to a physiological concentration, caused no functional
damage to the liver, as assessed by measurement of lactate
dehydrogenase activity in the medium (results not shown).
Antibodies
Hepatic lipase, purified by the method of Jensen and Bensadoun
[33], was used to immunize a goat as described elsewhere [34].
The IgG fraction was purified from plasma by two successive
precipitations with 50 %-satd. (NH4)2SO4 and 17 %-satd. Na2SO4
respectively, followed by extensive dialysis against PBS. Final
protein concentration was 20 mg/ml; 1 ml of this preparation
inhibits 3500 m-units ofhepatic lipase activity in a liver perfusate.
IgGs isolated similarly from the serum of a non-immunized goat
did not affect hepatic lipase activity. In a Western blot of a
heparin-containing liver perfusate, a single band of 58 kDa,
corresponding to hepatic lipase, was recognized by the specific
IgG preparation, but not by the control IgGs (results not
shown).
Monoclonal antibodies against hepatic lipase have been de-
scribed previously [34]. A mixture of hybridoma supernatants of
the five different clones was used in the present study. The titre
of this preparation was about 20 m-units/ml.
Hepatic lipase and lipoprotein lipase activity assays
Lipoprotein lipase activity was measured by using a glycerol-
stabilized glycerol [9, 10(n-3H)]trioleate suspension as described
by Nilsson-Ehle and Schotz [35]. To avoid any possible con-
tamination with hepatic lipase activity, samples were pre-
incubated with an anti-(hepatic lipase) specific polyclonal anti-
body [34]. The samples were mixed with anti-(hepatic lipase)
specific IgG (1/1, v/v) and preincubated for 5 min at 25 °C,
followed by 25 min on ice, before the lipase assay was carried
out.
Hepatic lipase activity was determined in the perfusion media
and in post-nuclear supernatants of a 2.5 % (w/v) liver homo-
genate in PBS containing 5 units/ml heparin (15 s, Polytron
setting 4). Hepatic lipase was measured during a 30 min in-
cubation at 30 °C by using an artificial glycerol [9,10(n-3H)]-
trioleate emulsion in gum arabic at 1.0 M NaCl, pH 8.5 [36].
Lipoprotein lipase activity is not detectable under these con-
ditions. All the lipase activity measured could be completely
suppressed by anti-hepatic lipase antibody (results not shown).
E.i.i.s.a. for rat hepatic lipase
The amount of hepatic lipase protein was determined by a solid-
phase e.l.i.s.a. [37]. Polystyrene microtitre plates (96 wells) were
coated with the goat anti-(hepatic lipase) IgG. After blocking
with gelatin, the wells were successively incubated with sample,
monoclonal antibodies (diluted 5-fold) and alkaline phosphatase-
conjugated goat anti-mouse IgG (diluted 1: 500) in the presence
of 1 M NaCl, 0.1 % Tween 20 and 0.5% BSA to decrease non-
specific binding. Finally, alkaline phosphatase activity was
measured with p-nitrophenol phosphate as the substrate in a
Titertek EIA analyser. Absorbances at 405 nm were read against
a standard curve for partially purified hepatic lipase.
Materials
All chemicals used were of analytical grade. Heparin
(Thromboliquine) was purchased from Organon-Teknika
(Boxtel, The Netherlands) and BSA from Sigma (St. Louis, MO,
U.S.A.). Glycerol [9,10(n-3H)]trioleate (sp. radioactivity
1 Ci/mmol) was obtained from Amersham International,
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Amersham, Bucks., U.K. Synacthen was from Ciba-Geigy A. G.,
Basel, Switzerland. Alkaline phosphatase-conjugated anti-mouse
IgG was purchased from Tago, Burlingame, CA, U.S.A.
RESULTS
Liver perfusion with lipase-containing media
The livers of normally fed rats were perfused with a medium
containing either partially purified hepatic lipase or lipoprotein
lipase. During a O min recirculating perfusion with various
amounts ofhepatic lipase (2000-7000 m-units), the lipase activity
and hepatic lipase mass in the medium did not change (Figure 1).
Similar results (not shown) were obtained during perfusion at
4 °C and 37 'C. The lipase activity in the livers also was essentially
unaffected (without perfusion 820+100 m-units/g of liver, after
150
S 1001
C._
.
Ij 50
0 2 4 6 1
Time (min)
100
o5I
.0
0.
50 3
1
8 10 12
Figure 1 Binding of hepatic lipase (HL) to perfused rat liver
Rat livers were perfused at 4 0C with various amounts of hepatic lipase (up to 7000 m-units).
At different time intervals samples were withdrawn and lipase activity (O) or amount of hepatic
lipase protein (0) was determined in the perfusate. The results are expressed as % of the initial
lipase activity present in the perfusate (100%). The results of three different experiments are
given (means + S.D.).
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Figure 2 Binding of llpoprotein lipase (LPL) to perfused rat liver
Lipoprotein lipase was perfused through rat liver in recirculating mode (0 0) or without
rat liver (O----0) at 4 0C with a medium containing lipoprotein lipase. Lipoprotein lipase
activity was measured in the recirculating perfusion media. After the recirculating perfusion the
livers were perfused one way with KRB, followed by perfusion with a heparin-containing medium
(5 units/ml) during 5 min. Lipoprotein lipase activity was measured in the perfusate at the end
of the recirculating perfusion and at the end of the heparin perfusion (+ * * +). The initial
lipase activity present in the perfusate is taken as 100% (200-1500 m-units). Results are
expressed as means+ S.D. of three separate experiments.
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Figure 3 Unsaturable binding of lipoprotein lipase to perfused rat liver
Rat livers were perfused with media containing different amounts of lipoprotein lipase.
Lipoprotein lipase activity was measured in the perfusate just before and after the recirculating
perfusion. The measured differences in lipase activity are expressed as m-units of lipoprotein
lipase (LPL) bound.
Table 1 Hepatc lipase binding In ACTH-treated rats
Livers of control and ACTH-rats were perfused with heparin- or 0.3 M NaCI-containing KRB.
The perfusions were continued by recirculating perfusion with a hepatic-lipase-containing
medium. Hepatic lipase activity was measured in the heparin and NaCI perfusates (HL released)
and in the hepatic-lipase-containing media. The loss of lipase activity from the medium during
the recirculating perfusion represents the bound lipase. The activities measured are expressed
as m-units of lipase/g of liver. The Table shows means+S.D. of 3-5 different experiments.
Lipase activity (m-units/g of liver)
Controls ACTH
HL released by heparin 763 + 219 248+ 61
HL binding after heparin pre-perfusion 90 + 24 88 +12
HL released by 0.3 M NaCI 532 +154 152 +16
HL binding after NaCI pre-perfusion 541 +164 212 + 60
perfusion 780 + 75 m-units/g of liver; n = 3). In contrast, during
perfusion with lipoprotein lipase, the lipoprotein lipase activity
in the medium fell within 5 min to 30 % of the initial value. The
lipoprotein lipase activity lost from the medium during the
perfusion was completely recovered by subsequent heparin
perfusion (Figure 2). The amount of lipoprotein lipase which
bound to the liver increased linearly with the amount of
lipoprotein lipase present in the perfusion medium up to 1500 m-
units (Figure 3). In control experiments, the perfusion protocol
was carried out without a liver. Under these conditions no
change in either hepatic lipase or lipoprotein lipase activity in the
medium was observed (results not shown).
Binding of hepatic lipase to heparin-pre-perfused liver
The obvious lack of binding of hepatic lipase to intact livers
raised the question whether the binding capacity of the liver was
completely utilized or whether the hepatic lipase preparations
used were unable to bind to the liver in the experimental set-up.
Therefore, livers were pre-perfused with a heparin-containing
medium during 5 min to deplete the extracellular pool of hepatic
lipase. More than 80% of the total lipase activity is released from
the liver in this way (Table 1). The heparin pre-perfusion of the
livers was followed by a perfusion with a hepatic-lipase-con-
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Figure 4 Binding of hepatic lipase to heparin-perfused livers
Rat livers that had been pre-perfused with heparin (5 units/ml) were perfused with media
containing different amounts of hepatic lipase. Hepatic lipase was measured in the pertusate
before and after the recirculating perfusion. The Figure represents a typical example of seven
different experiments. In the inserft, the time course of the binding of hepatic lipase (HL) is given.
Hepatic lipase activity was measured in samples of the perfusate just before and after the
passage through the liver. The porfacaval differences (% of hepatic lipase activity bound) in
lipase activities are expressed as % of the hepatic lipase in the medium, just before passage
through the liver. Values in the inserf are the means+ S.D. of 7 different experiments.
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Figure 5 Binding of hepatic lipase to salt perfused livers
Rat livers that had been pre-perfused with 0.3 M NaCI were perfused in recirculating mode with
media containing hepatic lipase. Hepatic lipase activity was measured in the recirculating
perfusate (-). After the recirculating perfusion, livers were washed and perfused with heparin
(5 units/ml) during 5 min. Hepatic lipase was also measured in the perfusate at the end of the
recirculating perfusion and at the end of the heparin perfusion (0). The Figure represents a
typical example of four different experiments.
taining medium as described above. Up to 1000 m-units of
hepatic lipase activity were lost from the medium (Figure 4). The
binding of the lipase was very rapid. During the first 30 s 80%
of the lipase activity perfused through the liver was bound. After
the first 1 min the percentage of the lipase bound during a single
passage rapidly declined (Figure 4 insert). The amount of lipase
activity bound did not increase even ifmore than 4000 m-units of
hepatic lipase was perfused through the livers. The hepatic lipase
activity that was bound to the liver during the perfusion could be
completely recovered in the medium by heparin perfusion. The
Figure 6 Binding of hepatic lipase (HL) to perfused livers: effect of ACTH
treatment
Livers of control (-) and ACTH-treated (0) rats were perfused with media containing hepatic
lipase as described in the legend to Figure 1. The Figure shows means+ S.D. of three different
experiments.
maximal amount of hepatic lipase which bound to the liver was
10-20% of the activity originally present in the liver (Table 1:
90 + 24 m-units/g of tissue). These results indicated that hepatic
lipase from the medium can be bound to the liver during
perfusion, but that the capacity of the liver to bind hepatic lipase
is fully utilized in control rats. In addition, it appears that
heparin lowers the binding capacity of the livers greatly, possibly
by removing a hepatic-lipase-binding component from the liver.
NaCI perfusion
In view of these findings, we investigated the possibility of
removing hepatic lipase from the liver without affecting the
binding capacity. In a series of experiments using 0.15 M to
0.75 M NaCl in the perfusion medium, we found that 0.3 M
NaCl in the medium released 60% of the liver hepatic lipase
activity into the perfusate within 5 min (Table 1). Upon sub-
sequent perfusion with heparin the remaining hepatic lipase
activity (about 20%) was released from the liver.
Perfusion of 0.3 M NaCl-pre-perfused livers with a hepatic-
lipase-containing medium led to a fall in hepatic lipase activity in
the medium by 5000 m-units (Figure 5). This lipase activity
could be recovered in the medium by heparin perfusion (Figure
5). Moreover, it can be seen that the amount of hepatic lipase
activity released by 0.3 M NaCl perfusion equals the amount of
hepatic lipase bound after subsequent perfusion of these salt-pre-
perfused livers with hepatic-lipase-containing medium (532 + 154
and 541 164 respectively).
Hepatic lipase binding in control and ACTH-pre-treated rats
Previously we have shown that ACTH treatment leads to a
diminished hepatic lipase activity in rat liver [12,30]. To study
whether under these conditions binding capacity of the liver for
hepatic lipase is also saturated, we performed perfusion experi-
ments as described above with livers of ACTH-treated animals.
During perfusion of ACTH-pre-treated livers with a hepatic-
lipase-containing medium, no change in hepatic lipase activity
occurred, indicating a complete utilization of the hepatic-lipase
binding capacity of the livers (Figure 6). Subsequently, we
studied binding of hepatic lipase to heparin-pre-perfused and to
0.3 M NaCl-pre-perfused livers in ACTH-treated animals. Hep-
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Figure 7 Binding of hepatic lipase to salt-pre-perfused livers: effect of
ACTH treatnent
Livers of control (0) and ACTH-treated (e) rats, pre-perfused with 0.3 M NaCI, were perfused
in recirculating mode with hepatic-lipase-containing media. At different time intervals, hepatic
lipase activities were measured in the media. The loss of lipase activity from the medium,
divided by the liver weight, represents the amount of lipase activity bound per g of liver. The
Figure shows mean+ S.D. of 3-5 different experiments.
arin perfusion released 248 + 61 m-units/g of liver from the livers
(Table 1). Perfusion of these livers with hepatic lipase led to a
binding of 88+ 12.4 m-units of hepatic lipase/g of liver, which is
equal to the amount of hepatic lipase that can be bound to a
heparin-pre-perfused control (not ACTH-pre-treated) liver. Per-
fusion of ACTH-pre-treated livers with 0.3 M NaCl released
152 + 16 m-units of hepatic lipase/g of liver (Table 1). Perfusion
of these salt-pre-perfused livers with a medium containing
5000-8000 m-units of hepatic lipase led to a fall in activity in the
medium of about 2500 m-units (Table 1). Comparison of the
binding of hepatic lipase to the livers after the 0.3 M NaCl
perfusion between control and ACTH-rats revealed a 70% lower
maximal binding in the ACTH-rats than in the controls (Figure
7).
DISCUSSION
In previous studies, using isolated non-parenchymal liver cells, a
decrease in the amount of specific binding sites was observed on
non-parenchymal liver cells isolated from ACTH-treated rats
[12]. A decrease in the amount of binding sites for hepatic lipase
is hardly of physiological importance if only a few binding sites
are occupied. A decrease in the binding capacity will be of much
more importance for the expression of hepatic lipase activity if
all binding sites are occupied. In this paper we show that in
normal rat liver all binding sites for hepatic lipase are occupied
in situ, as at both 4 °C and 37 °C no additional binding of hepatic
lipase was observed if rat livers were perfused with hepatic-
lipase-containing media. Also, in livers ofACTH-rats no binding
of hepatic lipase was found during perfusion with lipase-con-
taining medium. In these livers total extracellularly located lipase
activity is greatly lowered [12,30]. We have previously shown by
immunotitration that the specific activity of hepatic lipase in
ACTH-rats is not altered [12]. Therefore it can be concluded
that also in livers of ACTH-rats all binding sites are occupied,
indicating a lowered number of binding sites. The complete
occupancy of the hepatic-lipase binding sites indicates that a
decrease in the binding capacity leads to a decreased activity of
the enzyme. In contrast with hepatic lipase, lipoprotein lipase did
bind to normal rat liver. More than 80% of lipoprotein lipase
was bound under the perfusion conditions used. The fact that
lipoprotein lipase, but not hepatic lipase, binds to perfused liver
shows for the first time that the binding site for hepatic lipase is
different from the hepatic binding site for lipoprotein lipase,
suggested previously on the basis of the different disappearance
rates of the two enzymes after injections of several size-
fractionated heparins [38]. Ifhepatic lipase, as generally assumed,
binds to heparan sulphate proteoglycans, the structural charac-
teristics of the proteoglycan(s) involved must be highly specific.
In contrast with lipoprotein lipase, which is bound to most
tissues and cells, hepatic lipase is only bound to the liver, adrenal
cortex and ovary [39,40]. Liver contains about 400 ,Iug of heparan
sulphates [41]. Three forms of heparan sulphate proteoglycans
have been isolated from rat liver, a peripheral proteoglycan,
a membrane-intercalated proteoglycan and a proteoglycan
associated with lysosomes [42,43]. Recently a novel heparan
sulphate in the extracellular matrix and the basement membranes
of the liver has been found [44]. The best characterized heparan
sulphate proteoglycan localized on the sinusoidal rat liver plasma
membrane has a molecular mass of 75 kDa [43,44]. Normal rat
liver contains about 7500 m-units of hepatic lipase activity.
Assuming a specific activity of hepatic lipase of 800 m-units/,ug
of protein and a molecular mass of 57 kDa [33,37], this amount
of hepatic lipase corresponds to 0.165 nmol of hepatic lipase. If
hepatic lipase is bound as a monomer in a 1: 1 ratio to its binding
site, 0.165 nmol of receptor molecules should be present in a
whole rat liver. If this proteoglycan would function as the specific
receptor for hepatic lipase in the liver, 0.165 nmol of receptor
molecules correspond to 8 ,ug of heparan sulphate/total liver,
indicating that only a small part of the heparan sulphates has the
structural characteristics necessary for the binding of hepatic
lipase. The nature of the hepatic-lipase binding sites is unknown.
From the experiments presented it is tempting to suggest that
hepatic lipase is bound in two ways to the liver. Part of the lipase
(about 10% in normal liver) seems to be bound to a site which
remains intact after perfusion with heparin, representing a
heparin-resistant or heparin-insensitive binding site. The other
hepatic-lipase binding site is removed or inactivated by heparin,
representing a heparin-sensitive or heparin-releasable binding
site. Possibly, this binding site consists of a protein releasable
from the liver by heparin, although inactivation of a binding site
by heparin cannot yet be excluded. Since the heparin-resistant
binding of hepatic lipase was similar in control and ACTH-rats,
this type of binding site seems not to be regulated, at least under
the conditions studied. It contributes from about 10% in controls
to about 30 % in ACTH-rats to the binding of the extracellularly
located hepatic lipase pool. The heparin-releasable or heparin-
sensitive binding site is greatly diminished in the ACTH-rats.
The lowering of this binding completely accounts for the lowered
hepatic lipase activity in the ACTH-rats. This suggests that via
this binding the expression of hepatic lipase may be regulated,
although regulation at the site of synthesis (secretion) of the
lipase also occurs [12]. A heparin-releasable protein (HRP)
binding lipoprotein lipase has been detected in bovine aortic
endothelial cells [20]. Whether the presumed hepatic-lipase bind-
ing protein is similar to or even identical with this lipoprotein
lipase binding protein is not clear. However, lipoprotein lipase is
not bound to this protein in the liver, since the binding of
lipoprotein lipase was not affected by prior heparin preperfusion.
The presence of at least two different binding mechanisms of
hepatic lipase to the liver raises questions about the functionality
of the differentially bound enzymes in relation to the localization
of the different binding sites. In addition, the finding that the
heparin-sensitive binding is lowered by ACTH treatment opens
the possibility that hepatic lipase expression in liver can be
regulated via the binding capacity for the enzyme.
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Studies are in progress in our laboratory to identify the specific
binding sites for hepatic lipase.
We thank Miss Ina Kalkman and Miss Lianne Kloet for their excellent technical
assistance.
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